AGM
DNLI icon

Alpine Global Management’s Denali Therapeutics DNLI Stock Holding History

Alpine Global Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-26,271
Closed -$458K – 284
2019
Q4 		$458K Buy
+26,271
New +$437K 0.1% 172

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Alpine Global Management's DNLI Position: Q1 2020 in Review

Alpine Global Management sold out of Denali Therapeutics (DNLI) in Q1 2020, closing a stake of 26,271 shares — an estimated $458K sold.

Alpine Global Management first reported a position in DNLI in Q4 2019 and held it in 1 quarter. The position peaked at $458K in Q4 2019. 128 funds tracked by Wall St. Rank hold DNLI as of Q1 2020.

  • Alpine Global Management reported no remaining Denali Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Alpine Global Management sold 26,271 Denali Therapeutics shares in Q1 2020, an estimated $458K.
  • Alpine Global Management first reported a position in Denali Therapeutics in Q4 2019 and held it in 1 quarter.
  • Alpine Global Management's Denali Therapeutics position peaked at $458K in Q4 2019.
  • 128 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.